Clinical Trial Update: Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated GLPG0634 (filgotinib) for efficacy and safety in active Crohn's disease. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• GLPG0634 (filgotinib) (filgotinib)

Snippet

Sponsor: Galapagos NV | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED